Meitheal Pharmaceuticals has Docetaxel Injection, USP Now Available

Share Facebook icon Twitter icon Linkedin icon

Meitheal Pharmaceuticals (Meitheal) is pleased to announce that we have launched Docetaxel Injection, USP, 80 mg per 8 mL (10 mg per mL) in a multi-dose vial and Docetaxel Injection, USP, 160 mg per 16 mL (10 mg per mL) vial in a multi-dose vial.

Meitheal will offer Docetaxel Injection, USP in a pack of 1 vial for both presentations.


Docetaxel Injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. Docetaxel Injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.

For full prescribing information, please click on the following link.

Learn more about Docetaxel Injection, USP

This Website Uses Cookies

This website uses cookies to help us give you the best experience when you visit. By clicking “Accept Cookies,” you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can read more about our use of cookies in our Privacy Policy.

Accept cookies Reject cookies